Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells.

Content Provider	Semantic Scholar
Author	Battaglia, Manuela Stabilini, Angela Roncarolo, M. G.
Copyright Year	2005
Abstract	Rapamycin is an immunosuppressive compound that is currently used to prevent acute graft rejection in humans. In addition, rapamycin has been shown to allow operational tolerance in murine models. However, a direct effect of rapamycin on T regulatory (Tr) cells, which play a key role in induction and maintenance of peripheral tolerance, has not been demonstrated so far. Here, we provide new evidence that rapamycin selectively expands the murine naturally occurring CD4(+)CD25(+)FoxP3(+) Tr cells in vitro. These expanded Tr cells suppress proliferation of syngeneic T cells in vitro and prevent allograft rejection in vivo. Interestingly, rapamycin does not block activation-induced cell death and proliferation of CD4(+) T cells in vitro. Based on this new mode of action, rapamycin can be used to expand CD4(+)CD25(+)FoxP3(+) Tr cells for ex vivo cellular therapy in T-cell-mediated diseases.
File Format	PDF HTM / HTML
DOI	10.1182/blood-2004-10-3932
Alternate Webpage(s)	http://www.bloodjournal.org/content/bloodjournal/105/12/4743.full.pdf?sso-checked=true
Alternate Webpage(s)	http://www.bloodjournal.org/content/bloodjournal/105/12/4743.full.pdf?ck=nck&sso-checked=true
Alternate Webpage(s)	http://www.bloodjournal.org/content/bloodjournal/early/2005/03/03/blood-2004-10-3932.full.pdf?sso-checked=true
PubMed reference number	15746082
Alternate Webpage(s)	https://doi.org/10.1182/blood-2004-10-3932
Journal	Medline
Volume Number	105
Issue Number	12
Journal	Blood
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article